Sierra Oncology, Inc. (SRRA)

Today's Latest Price: $16.03 USD

0.02 (-0.12%)

Updated Jan 20 6:55pm

Add SRRA to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

Sierra Oncology Inc (SRRA) Price Targets From Analysts

The tables below show price targets and recommendations from analysts covering Sierra Oncology Inc.

Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
4 $32 $21 $27.75 $16.05 72.9%

SRRA Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.25 2 2 0 0 0 NA

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • The upside potential (average analyst target price relative to current price) of SRRA is greater than 84.32% of all US stocks.
  • SRRA has a lower variance in analysts' estimates than 30.93% of stocks in the small market cap category.
  • SRRA has a higher average analyst price target than 66.96% of stocks in the small market cap category.
  • SRRA has a greater number of analysts covering the stock than 35.45% of Pharmaceutical Products stocks.
  • Sierra Oncology Inc's percent of analysts bearish on the stock is lower than nearly 100% of all US stocks.
  • Sierra Oncology Inc's percentage of analysts bullish on the stock is higher than nearly none of all US stocks.
  • SRRA has a lower change in bullishness amongst analysts than nearly 100% of all US stocks.

Stocks similar to Sierra Oncology Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are SLGL, ATHA and AKUS.

Is SRRA a Buy, Hold or Sell? See the POWR Ratings now!



Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7752 seconds.